Insulet PODD Stock options excluded as their inclusion would be anti-dilutive (in shares)

Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies

West Pharmaceutical ServicesWST

——

AbbottABT

——

Other financials

Income statement

See full

Revenue$761.7M+33.9%

Gross profit$529.0M+29.3%

Operating income$122.1M+37.5%

Net income$91.1M+157%

EPS (diluted)$1.30+160%

Balance sheet

See full

Cash & equivalents$480.4M-62.6%

Total debt$969.7M-45.5%

Total equity$1.3B-2.1%

Total assets$3.0B-15.1%

Cash flow

See full

Operating cash flow$113.8M+78.4%

CapEx$24.3M+97.6%

Free cash flow$89.5M+73.8%

Valuation

See full

Market cap$10.1B-19.9%

Enterprise value$10.59B-19.4%

P/E33.3×+2.0×

P/S3.5×-2.3×

Profitability

See full

Gross margin71%+0.6pp

Operating margin17.5%+2.0pp

Net margin10.4%-7.9pp

FCF margin14.3%+1.1pp

Returns & leverage

See full

Return on equity23%-14.9pp

Debt / equity0.7×-0.6×

Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's stock options excluded as their inclusion would be anti-dilutive (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insulet's stock options excluded as their inclusion would be anti-dilutive (in shares)?: Insulet (PODD) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 764K in Q1 2026.
How has Insulet's stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?: Insulet's stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 36.4% year-over-year, from 560K to 764K.